This study is no longer recruiting. We hope to get more studies in this field soon, especially considering the rates of skin cancer in Australia. If you are interested in this area, please call us on 9587 4277 to discuss your options.
LeoPharma a 14 month trial using Picato gel across the face, to treat widespread actinic keratosis. The active ingredient is Ingenol Mebutate, which is a plant extract. Picato is currently on the market for treatment of actinic keratosis, however it is only licensed on small areas (<25cm2), which is often not sufficient for our population. During the trial the gel is applied for up to 3 days (same as the current licensed treatment). The patient is then followed up regularly for 8 weeks, and then sparingly for 12 months.